{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-026595","form_type":"8-K","ticker":"BLFS","cik":"0000834365","company_name":"BIOLIFE SOLUTIONS INC","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.692757+00:00","generated_at":"2026-06-22T02:26:18.259434+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioLife Q3 revenue $40.7M (+21% YoY); biopreservation media +50%; tightens FY22 guidance to $160-164M","bullets":["GAAP net loss of $10.0M ($0.23 loss per share) vs net income of $79K in Q3 2021.","Adjusted EBITDA turned positive at $1.4M versus negative $2.1M in Q3 2021.","Cell Processing platform revenue $18.1M (+57% YoY); Freezer/Thaw Systems $15.3M (-13% YoY).","Cash, equivalents and marketable securities $62.1M; borrowed $20M via term loan in Q3.","FY2022 revenue guidance narrowed to $160-164M from $160-166M; organic growth expected 37-40%."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-026595","json":"https://secwatch.observer/filing/0001437749-22-026595.json","markdown":"https://secwatch.observer/filing/0001437749-22-026595.md","text":"https://secwatch.observer/filing/0001437749-22-026595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/834365/000143774922026595/0001437749-22-026595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/834365/000143774922026595/bioli20221109_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:26:18.259434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42f6cb894e510495d94f869a9578f2ea5f751623","claim":"BIOLIFE SOLUTIONS INC reported the three and nine months ended September 30, 2022 results: revenue Total revenue for the third quarter of 2022 was $40.7 million. Guidance reaffirmed.","evidence_excerpt":"On November 9, 2022, BioLife Solutions, Inc. issued a press release announcing financial results and operational highlights for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/834365/000143774922026595/0001437749-22-026595-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2022"},{"label":"Revenue","value":"Total revenue for the third quarter of 2022 was $40.7 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}